Bring cell therapy close to your patients.
Your program already manages these patients. We help you build the capability to treat them with cell therapy, starting with clinical trials and growing into a full commercial service line.
You are referring out patients you could treat.
Every year, large multispecialty health systems send cell therapy candidates to distant academic centers. Patients travel for weeks, families are displaced, and the health system loses continuity of care along with the revenue that follows the patient. Cell therapy is moving to earlier lines of treatment and more diseases, so the number of these patients is growing. The question is no longer whether community and regional systems will deliver cell therapy, but which ones will do it well.
A staged path that fits your program.
Building a cell therapy program from a standing start is expensive and slow, so we stage it. For most sites we recommend beginning with clinical trials: sponsors provide product, protocol, and training, your team builds real experience, and the trial work supports FACT accreditation. From there you transition to commercial products with the workflows, contracts, and staff already in place. Some programs have reasons to start on the commercial side instead, and we support that path with the same rigor. Either way, each stage has a defined deliverable and you decide when to move to the next.
Five ways we help, in the order you need them.
Readiness and viability assessment
A site-specific review of your clinical, operational, and financial readiness for cell therapy: patient volume, apheresis and pharmacy capacity, inpatient and outpatient pathways, accreditation, payer mix, and the business case. You get an executive roadmap with what to build, in what order, and what it will return.
Capability build
Hands-on support to close the gaps the assessment finds: unit design, governance, roles and staffing, standard operating procedures, training and competency, toxicity management, data and registry reporting, and product onboarding with manufacturers.
Clinical trial access
Sponsors are looking for capable sites outside the academic centers. We help you present your program's capabilities accurately, identify trial opportunities that fit your patients and your capacity, and move through feasibility, contracting, and activation faster. You choose which trials to pursue; sponsors choose their sites. Your team gains cell therapy experience with sponsor support, and your patients gain access to therapies before they are commercially available.
Payer and reimbursement
Cell therapy economics break in specific places: prior authorization, single case agreements, coding and charge capture, and denials. We map where margin leaks across the patient journey and fix the root cause, so a program that delivers excellent care also sustains itself financially.
Operations and scale
Best-in-class people and processes for business development, finance, and clinical operations, embedded with your team or delivered as managed services, so you can grow volume without losing quality.
We have built and run the program you are building.
Our team and advisors come from Moffitt Cancer Center and other successful cell therapy programs, where cell therapy is delivered at some of the highest volumes in the world. We know what a functioning program looks like on a Tuesday afternoon, not just in a slide deck, and we bring that operating knowledge to your site: the SOPs, the payer playbooks, the staffing models, the value drivers and the judgment about what matters first.
From referring out to building in: a regional health system's first year.
The starting point
A regional health system with a strong oncology service line and a successful bispecific antibody program was sending every CAR-T candidate to an academic center hours away. Leadership wanted to keep those patients, but had no CAR-T experience in house, no medical director, no business case, and no clear view of what a program would cost or how long it would take.
What we did
Over a 6-week assessment, our team spent time on site, interviewed functional leaders across medical, nursing, pharmacy, lab, revenue cycle, and administration, and evaluated the program against the requirements of a working CAR-T service. The deliverable was a launch model built for speed: a minimum viable program using an existing FACT-accredited collection partner, inpatient treatment, just-in-time product logistics, and a dedicated coverage model; a 12-month launch roadmap sequenced around the one true gating item, hiring a CAR-T medical director; a capital-light startup budget; and a three-year scaling plan.
What happened next
Within four months of the final readout, the system had secured executive sponsorship and a board-level presentation, posted and recruited for a CAR-T medical director with program-building experience, and begun the internal pro forma using our roadmap as the resource plan. Leadership told us the assessment moved them several months ahead and strengthened their physician recruiting, because they could show candidates a plan. Their target: treating patients within 18 months of completing Launch Point.
Why it worked
The recommendations were operational, not aspirational. Each gap came with an owner, a fix, and a place in the sequence, so a team with no cell therapy background could act on it immediately.
“The PAGONA report laid out exactly what we’d need. It accelerated us by several months and helped us recruit.”Oncology service line executive
Launch Point for readiness. SOP Library for build. Margin Map for reimbursement.
Each packages a piece of operating know-how so your team does not rebuild it from scratch. Full descriptions live on the Solutions page.
Find out what it would take.
A readiness conversation is a no-obligation call that tells you where your program stands today and what the next step would be.